CME INFORMATION FOR THE CLINICAL CARE SESSION ONLY

The University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA gratefully acknowledge the educational grants provided by and Novartis Gene Therapies.

Target Audience Healthcare providers who diagnose and care for people with SMA, including physicians, nurse practitioners, physician assistants and nurses, pediatric and adult specialists including neurologists, pulmonologists, rehabilitation medicine, genetics, orthopedic surgery, palliative care, physical and occupational therapists, speech and language pathologists, pharmacists, nutritionists, genetic counselors, social workers, respiratory therapists, and trainees in the above disciplines.

Educational Objectives After completing this activity, the participant should be better able to:

1. Demonstrate knowledge of multidisciplinary team roles and responsibilities in care management to optimize SMA outcomes. 2. Describe the existing and evolving treatment options for patients with SMA. 3. Describe the impact of new treatments on the SMA phenotype. 4. Analyze the treatment options for management of infants with SMA identified by SMA newborn screening. 5. Demonstrate knowledge of the risk for mental health complications of SMA. 6. Describe the application of mental health screening tools for SMA outpatient use.

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin‒Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA. The University of Wisconsin‒Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

American Medical Association (AMA) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pediatrics: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Academy of Physician Assistants (AAPA): The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 5.5 ANCC contact hours.

Accreditation Council for Pharmacy Education (ACPE) The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 5.5 hours/0.55 CEUs of CPE credit. Credit can be earned by documented attendance and by successfully completing the assessment. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Universal Activity Number (UAN) JA0000358-9999-21-100-L01-P, 5.5 hours/0.55 CEUs

American Psychological Association (APA): Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

ASWB Approved Continuing Education (ACE) Social Work Credit: As a Jointly Accredited Organization, the University of Wisconsin– Madison ICEP is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The University of Wisconsin–Madison ICEP maintains responsibility for this course. Social workers completing this course receive 5.5 live continuing education credits.

Wisconsin Physical Therapy Association (WPTA) This activity has been approved by the APTA Wisconsin for 5.00 credits.

Wisconsin Occupational Therapy Association (WOTA) This activity has been approved by WOTA for 5 credits.

Continuing Education Units The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for .55 continuing education units (CEUs) or 5.5 hours.

National Society of Genetic Counselors This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

FACULTY AND SPONSOR DISCLOSURES It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.

DISCUSSION OF UNLABELED/ UNAPPROVED USES NAME ROLE(S) FINANCIAL RELATIONSHIPS DISCLOSURE OF DRUGS/DEVICES IN PRESENTATION? Kapil Arya, MBBS Presenter No relevant relationships with ineligible companies to disclose No Mei Baker, MD Presenter No relevant relationships with ineligible companies to disclose No Planner, AveXis; ; Novartis; PTC Therapeutics, Inc. (All Vanessa Battista, RN, MS Presenter Contractor) No William Bell, PharmD, MBA Planner No relevant relationships with ineligible companies to disclose N/A Lisa Belter, MPH Presenter No relevant relationships with ineligible companies to disclose No ; Biogen; Catabasis; CSL Behring; FibroGen; Novartis; PTC Therapeutics, Inc.; ; Sarepta Therapeutics, Inc.; Summit, WaVe (All Grant); Audentes; Biogen Idec; Cytokinetics; Genentech; Momenta Pharmaceuticals, Inc.; Novartis Pharma; NS Pharma; PTC Planner, Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock; John Brandsema, MD Presenter WaVe (All Contractor) No Karlla Brigatti, MS, CGC Presenter Biogen, Inc.; Novartis (Grant); Novartis (Contractor) No Jin Yun Chen, MS, CGC Planner No relevant relationships with ineligible companies to disclose N/A Planner, Biogen, Inc.; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Thomas Crawford, MD Presenter Scholar Rock (All Contractor) No Arlene D’Silva, PhD Presenter No relevant relationships with ineligible companies to disclose No Paul Drake, MD Presenter No relevant relationships with ineligible companies to disclose No Planner, Bakri Elsheikh, MD Presenter Biogen (Contractor and Grant); Genentech (Contractor) No Planner, Al Freedman, PhD Presenter Genentech; Novartis (Both Contractor) No Planner, Melissa Gibbons, MS, CGS Presenter Biogen; Novartis (Both Grant) No Jennifer Hubbell, BS Planner No relevant relationships with ineligible companies to disclose No Becky Hurst-Davis, MS, RD Planner No relevant relationships with ineligible companies to disclose N/A Brian Jackson, MD, MA Presenter No relevant relationships with ineligible companies to disclose No Biogen, Inc.; Novartis Pharma; Sarepta Therapeutics, Inc. (All Chamindra Konersman, MD Planner Contractor) N/A Richard Kravitz, MD Planner AveXis; Biogen, Inc.; Santhera (All Contractor) N/A ASPA Therapeutics; Biogen; Genentech; Novartis; (All Kristin Krosschell, PT, DPT Planner Contractor); Biogen (Grant) N/A Oren Kupfer, MD Planner No relevant relationships with ineligible companies to disclose N/A Cathy Means, MS Planner No relevant relationships with ineligible companies to disclose N/A Biogen, Inc.; F. Hoffmann-LaRoche; Genentech USA, Inc.; Jacqueline Montes, PT, EdD Presenter Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor) No Meghan Moore, PT, DPT Presenter Biogen, Inc.; Genentech (Both Contractor) No Pamela Mosher, MD Presenter No relevant relationships with ineligible companies to disclose No Planner, Diane Murrell, LCSW Presenter No relevant relationships with ineligible companies to disclose No Avexis; Biogen, Inc.; F. Hoffmann-La Roche; Genentech; Leslie Nelson Planner Novartis; Scholar Rock (All Contractor) N/A Planner, Julie Parsons, MD Moderator Biogen; Genentech; Novartis; Scholar Rock (All Contractor) No Avexis; Biogen; Capricor; Genentech; NSpharma; PTC Therapeutics, Inc.; RegenxBio; Sarepta Therapeutics, Inc.; Vamshi Rao, MD Moderator Scholar Rock; Watermark (All Contractor) No Planner, Samuel Rosenfeld, MD Presenter OrthoPediatrics Corp. (Contractor) No Peter Schochet, MD Planner No relevant relationships with ineligible companies to disclose N/A Planner, Medical Mary Schroth, MD Director Audentes Therapeutics (Contractor) No Marisa Schwab, MD Presenter No relevant relationships with ineligible companies to disclose No Edward Smith, MD Planner Biogen; Genentech; Novartis (All Contractor) N/A Brian Snyder, MD, PhD Presenter Alcyone; OrthoPediatrics Corp. (Both Contractor) No Anne Stratton, MD Planner No relevant relationships with ineligible companies to disclose N/A Stacey Tarrant, RD, LDN Planner No relevant relationships with ineligible companies to disclose N/A Jane Taylor, MD Planner No relevant relationships with ineligible companies to disclose N/A Laura Watne, MD, RD Planner No relevant relationships with ineligible companies to disclose N/A Elanda Williams, MA Planner No relevant relationships with ineligible companies to disclose N/A Amy Xu, BS Presenter No relevant relationships with ineligible companies to disclose No

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by, or on, patients. The ACCME does not consider providers of clinical services directly to patients to be commercial interests.